ITeos Therapeutics EBIT Margin 2019-2025 | ITOS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

ITeos Therapeutics ebit margin from 2019 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

ITeos Therapeutics ebit margin from 2019 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$248.3B
Amgen (AMGN)	$155.9B
Gilead Sciences (GILD)	$142.4B
Vertex Pharmaceuticals (VRTX)	$99.3B
Bristol Myers Squibb (BMY)	$96.1B
GSK (GSK)	$81.1B
CSL (CSLLY)	$67.7B
Regeneron Pharmaceuticals (REGN)	$62.3B
Alnylam Pharmaceuticals (ALNY)	$59.1B
Argenex SE (ARGX)	$43.3B
Insmed (INSM)	$27.9B
BioNTech SE (BNTX)	$25.2B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.4B
Genmab (GNMSF)	$16B
Genmab (GMAB)	$15.7B
Illumina (ILMN)	$15.2B
Ascendis Pharma (ASND)	$12B
BioMarin Pharmaceutical (BMRN)	$11B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.9B
Exelixis (EXEL)	$10.3B
Moderna (MRNA)	$9.6B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Bio-Techne Corp (TECH)	$8.9B
Exact Sciences (EXAS)	$8.7B
Halozyme Therapeutics (HALO)	$8.5B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.1B